Introduction
Etrasimod is an oral, once-daily, selective sphingosine 1‑phosphate receptor modulator for the treatment of ulcerative colitis (UC). The positive benefit-risk profile of etrasimod was demonstrated in the phase 3 ELEVATE UC clinical programme and ENLIGHT UC trial.
Aims & Methods
EFFECT-UC (NCT06294925) is an ongoing, 52-week, prospective, non‑interventional study of adults with active UC starting etrasimod in routine care in the United Kingdom, Germany and Canada. In this interim analysis, we report corticosteroid (CS)-free symptomatic remission (symptomatic remission with no CS use in the prior 12 weeks) and changes from baseline in the short inflammatory bowel disease questionnaire (SIBDQ; scored 10–70) and the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F; scored 0–52) questionnaire at Week 12 and Week 24. We also report daily change from baseline in bowel urgency (BU), stool frequency subscore (SFS), rectal bleeding subscore (RBS) and patient-reported outcome (PRO)2, as well as symptomatic remission (SFS = 0 [or = 1 with a ≥ 1-point decrease from baseline] and RBS = 0), in the first two weeks of treatment. All data are as observed.
Results
As of 16 June 2025, 121 patients received etrasimod (mean age 40.2 years; mean modified Mayo score 4.9; 60.3% advanced therapy naïve; 27.0% baseline CS use). CS-free symptomatic remission was achieved by 23/63 (36.5%) and 18/38 (47.4%) patients at Week 12 and Week 24, respectively. Mean change from baseline (standard error of mean [SEM]) for SIBDQ was 7.6 (1.6) and 10.0 (2.0), and for FACIT-F was 3.8 (1.2) and 4.8 (1.8) at Week 12 and Week 24, respectively. Improvements in BU, SFS, RBS and PRO2 were seen in the first few days of treatment (Table). Mean change from baseline (SEM) in PRO2 was -0.5 (0.1) at Day 7 and ‑0.6 (0.2) at Day 14. Symptomatic remission was achieved by 20/101 (19.8%) patients at Day 7 and 30/98 (30.6%) patients at Day 14.
| Table. Patient-reported outcomes up to Day 14 in patients receiving etrasimod |
|---|
aBowel urgency was assessed using an 11-point NRS from 0 (“no urgency”) to 10 (“worst possible urgency”). bBowel urgency NRS: Day 3, N = 92; Day 7, N = 90; Day, 14 N = 88. cPRO2 is scored 0–6 and is a composite of SFS (scored 0–3) and RBS (scored 0–3), with higher scores indicating more severe disease activity. N, total number of patients with data available at a given time point; NRS, numerical rating scale; PRO2, patient-reported outcome 2; RBS, rectal bleeding subscore; SEM, standard error of mean; SFS, stool frequency subscore. |
| Day 3 (N = 95) | Day 7 (N = 101) | Day 14 (N = 98) |
| Change from baseline in bowel urgency NRS, mean (SEM)a,b | -1.22 (0.26)
| -1.66 (0.32)
| -1.93 (0.32)
|
Change from baseline in SFS, mean (SEM)
| -0.19 (0.07)
| -0.29 (0.08)
| -0.36 (0.09)
|
Change from baseline in RBS, mean (SEM)
| -0.19 (0.07)
| -0.20 (0.07)
| -0.27 (0.09)
|
Change from baseline in PRO2, mean (SEM)c
| -0.38 (0.11)
| -0.49 (0.12)
| -0.62 (0.15)
|
Conclusion
Etrasimod demonstrated clinically meaningful and rapid effectiveness, including CS-free symptomatic remission, among patients with active UC in this real-world cohort. Changes from baseline in quality of life and fatigue scores met the minimal clinically important difference for these scores by Week 24. Symptomatic PRO improvements were seen in the first few days of treatment. Future data cuts and analyses of the ongoing EFFECT-UC study will further confirm the effectiveness of etrasimod in routine clinical practice.
Disclosure
PMI: Grant: Celltrion, Janssen, MSD and Takeda; Lecture fees: AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, Janssen, MSD, Pfizer Inc, Sandoz, Sapphire Medical, Shire, Takeda, Tillotts, Warner Chilcott; Advisory fees: AbbVie, Arena, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Hospira, Janssen, MSD, Pfizer Inc, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, Warner Chilcott
RB: Speaker/consulting/moderator: AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Johnson & Johnson Innovative Medicine, Merck, Pfizer Inc, Takeda; Advisory boards: AbbVie, Bristol Myers Squibb, Celltrion, Janssen, Lilly, Pfizer, Takeda; Educational grants and sponsorships: AbbVie, Amgen, Celltrion, Eli Lilly, Johnson & Johnson Innovative Medicine, Kye Pharma, Merck, Organon, Pendopharm, Pfizer, Takeda; Travel support: AbbVie, Celltrion, Johnson & Johnson Innovative Medicine, Pfizer.
EB: Employee: Pfizer S.L.U., Shareholder: Pfizer Inc
MK, SKM, CC: Employees and Shareholders of Pfizer Inc
TM, SH: Employees: Pfizer Pharma GmbH, Shareholder: Pfizer Inc
AF, KW: Employees: Pfizer Canada Inc, Shareholder: Pfizer Inc
TK: Speaker/Advisory Committee/Board member: AbbVie, Alphasigma, Arena, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, Janssen, Lilly, MSD, Pfizer Inc, Roche, Takeda, UCB, Vifor
CM: Lecture and/or advisory fee: AbbVie, Alfasigma, Bristol Myers Squibb, Falk Foundation, Ferring, Galapagos, Gilead, Johnson & Johnson, Lilly, MSD, Pfizer Inc, Samsung, Takeda
EJ: Study participation: AbbVie, Alfasigma, Eli Lilly, Janssen, MSD, Pfizer Inc, Symbiopharm; Advisory boards: Alfasigma, Bristol Myers Squibb, Takeda; Grants: AbbVie, Ferring, Janssen
AW: Grant/Research Support: AbbVie, Alfasigma, Bristol Myers Squibb, Buhlmann, Eli Lilly, Falk Pharma, Galapagos, Janssen, Pfizer Inc, Sandoz, Takeda, Tillotts.
YL: Advisory board: AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Janssen, Pfizer Inc, Sandoz, Takeda; Speaker/moderator: AbbVie, Celltrion, Eli Lilly, Janssen, Pfizer Inc, Takeda
PH: Speaker and advisory fees: AbbVie, Celltrion, Falk Pharma, Janssen, Lilly, MSD, Takeda, Tillotts
SM: Grant: Baxter, B. Braun, Takeda; Lecture fees: AbbVie, Janssen, Johnson & Johnson, Pfizer Inc, Shire, Takeda; Advisory fees: Pfizer Inc, Pharmacosmos, Takeda
DRG: Speaker honoraria/advisory board: AbbVie, Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc
UH: Advisory fees: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celltrion, Janssen, Lilly, MSD, Mundipharma, Mylan Pharma, Pfizer Inc, Sandoz, Shield, Takeda, Vifor; Lecture fees: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celltrion, Falk Foundation, Ferring, Janssen, Lilly, MSD, Mundipharma, Mylan Pharma, Pfizer Inc, Sandoz, Shield, Takeda, Vifor